MicroPortNeuroTech Completes the First Batch of Clinical Implantations of NUMEN™ in Japan

Sendai, Japan —On November 3, MicroPort NeuroTech announced that the NUMEN™ Coil Embolization System (NUMEN™) completed its first batch of clinical implantations in Japan on 10 October. Within three weeks following this, 28 procedures were successfully carried out in 22 Japanese hospitals, receiving overall positive feedback. Adding to this achievement, on October 1, NUMEN™ received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for inclusion in public medical insurance.

The first implantation was jointly performed at Kohnan Hospital in Japan by Dr. Sakata, Dr. Hariu, and Dr. Honma. The patient, a 90-year-old woman, was preoperatively diagnosed with an irregularly shaped ruptured aneurysm in the ICA-PcomA segment, measuring approximately 7.8x6.5 mm. The surgeons opted for a simple coil embolization approach, using NUMEN™ for both the embolization filling and finishing stages, with a total of four NUMEN™ coils implanted (NUMEN™ MicroFinish 3x6, 2.5x4, 1.5x2, 1.5x2). During the procedure, NUMEN™ was noted for its smooth handling and ease of navigating into residual spaces, with successful and straightforward detachment, achieving effective aneurysm occlusion. After surgery, the medical team highly praised NUMEN™ for its smooth deliverability, good space seeking ability, stability in microcatheters during the finishing stages, and its simple, rapid, and reliable detachment process, enabling stable aneurysm embolization.

To date, both NUMEN™and the NUMEN™FR Detachment System have secured approvals in China, the EU, the USA, Korea, Brazil and Japan. They have successfully completed clinical implantation in several countries across Asia-Pacific, North America, and Europe. The recent achievement in Japan marks NUMEN™'s introduction into the 16th country or region. Its inclusion in Japan’s medical insurance system means NUMEN™ can benefit more local patients while significantly reducing their financial burden. This is a significant step in NeuroTech’s ongoing effort to expand global markets.

MicroPort NeuroTech continues to enhance its business operations and advance medical R&D. Looking ahead, MicroPort NeuroTech aims to provide more comprehensive solutions for patients worldwide suffering from cerebral vascular diseases.